A 73-year-old man with multiorgan failure requiring mechanical ventilation and haemodialysis developed herpes labialis infection during his stay in the ICU. This was treated with enteral acyclovir. He developed persistent neurologic impairment soon after acyclovir administration, which, over the course of seven days, progressed to coma, the aetiology of which was unclear. The computed tomograph (CT) of the brain and the cerebrospinal fluid (CSF) examination was normal. The electroencephalogram (EEG) showed generalized slowing. The possibility of acyclovir neurotoxicity was considered and the drug was discontinued. Haemodialysis was instituted and the patient made a complete neurological recovery. We believe that this is the first reported case of coma due to enteral acyclovir.
Acyclovir is widely used in the prophylaxis and treatment of herpes virus infection. It is an extremely well tolerated drug with a wide therapeutic index 1, 3 . Despite its impressive safety record, sporadic episodes of acyclovir-induced neuropsychiatric adverse effects have been reported [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . We describe a critically ill patient who developed severe neurotoxicity leading to coma following enteral acyclovir administration in the intensive care unit.
CASE HISTORY
A 73-year-old man was admitted to the intensive care unit for the management of acute respiratory failure, presumably secondary to amiodarone pulmonary toxicity. His past medical history was significant for coronary artery bypass grafting, chronic atrial fibrillation, non-sustained ventricular tachycardia and congestive heart failure. Management included endotracheal intubation, mechanical ventilation and later, tracheostomy. Bilateral pleural effusions, sepsis and acute renal failure requiring intermittent haemodialysis complicated his course in the ICU. His condition slowly improved, allowing weaning from vasopressor therapy and mechanical ventilation. At that time, the patient was alert, oriented and obeying commands. He required minimal doses of opioids and benzodiazepines for comfort.
The patient developed herpes simplex labialis infection, which was treated with enteral acyclovir 400 mg tds. The following day, the patient was sleepy, disoriented and developed episodes of intermittent agitation. Neurological examination was otherwise normal. All opioids and sedatives were stopped, with the expectation that his mental status would improve. However, over the next 48 hours his neurological condition continued to deteriorate. On clinical examination at that point, the patient responded to pain only, and had uncoordinated eye movements, tremors, facial and jaw myoclonus and increased reflexes and hypertonia in all muscle groups. His haemodynamic parameters, serum electrolytes, glucose and acid-base statuses were within normal limits. Metoclopramide was stopped without any benefit. He was on haemodialysis three times per week. CT scan of the brain was obtained on days 2 and 5 of acyclovir therapy: there was no evidence of intracranial hemorrhage or infarct. At lumbar puncture, opening pressure, protein and cell counts were normal: all viral and bacterial cultures were negative. EEG showed generalized slowing with no sign of seizure activity. On the seventh day of treatment with acyclovir, the patient became unresponsive and comatose.
Even though it was regarded as highly unlikely, the possibility of acyclovir neurotoxicity was considered and the medication was stopped. The frequency of haemodialysis was increased to hasten the elimination of the drug. After two haemodialysis sessions and three days from the point after which the drug was discontinued, the first signs of neurological recovery were noticed. In the next 24 hours the patient's neurological status rapidly improved and returned to baseline. Acyclovir levels were drawn, but the results were reported well after the patient had achieved full neurological recovery. Nevertheless, elevated trough levels in retrospect support the diagnosis of acyclovirinduced neurotoxicity ( Table 1 ). 
DISCUSSION
Patients in the ICU frequently develop mental status changes. Identifying the aetiology early is critical. Delay in diagnosis and treatment not only extends duration of ventilator dependency and ICU stay, but also exposes the patient to associated morbidity and mortality. The presentation can run the spectrum from excessive somnolence and lethargy to agitation, hallucination and delirium. Focal neurological deficit or seizures are usually absent. The aetiology is multifactorial 15 , frequently secondary to the administered drugs or metabolic encephalopathy. In the absence of improvement after discontinuation of potential neurotoxic agents, or if there is continued deterioration in the mental status, a search is made for an organic cause. Careful neurological examination, CT scan of the brain, and, if appropriate, CSF examination should be performed to assist diagnosis. This is the first reported case of coma caused by enteral acyclovir administration. Acyclovir is an important agent in the treatment and prophylaxis of herpes simplex virus infection. Even though the relative safety of acyclovir has been well established, serious adverse effects reported include reversible nephrotoxicity and neurotoxicity [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The risk factors for nephrotoxicity include administration by bolus as opposed to continuous infusion, underlying renal dysfunction and intravascular volume depletion 4 . Adair et al observed that the most important risk factor for the development of neurotoxicity was impaired renal function 5 . The primary route of elimination of acyclovir is renal, which accounts for 75 to 80% of its clearance 6 . In end-stage renal disease, the serum half-life of acyclovir is prolonged from two to three hours in normal persons to approximately 20 hours 7 . Reports indicate that plasma acyclovir concentrations are reduced approximately 60% by a single six-hour haemodialysis session 4 . The bioavailability of 15 to 30% may explain the safety of oral administration. Therefore it is not surprising that in 21 out of the 30 reported cases of acyclovir neurotoxicity, the drug was administered intravenously 5 .
The onset of symptoms of acyclovir-induced neurotoxicity develops usually within 24 to 72 hours after the start of therapy. Presenting signs include disorientation, hallucinations, delirium, tremors, ataxia, myoclonic jerks, slurred speech, seizures or focal neurological defects 5, 6, 8 . There are three reported cases of coma secondary to intravenous acyclovir administration 8 . Reported neuro-psychiatric effects with oral acyclovir are generally mild and include drowsiness, lethargy, agitation, inability to concentrate, dysarthria and delirium 10 . There is some evidence that acyclovir neurotoxicity is related to increased serum acyclovir concentration 8, 10 . The development of symptoms soon after beginning the therapy with acyclovir, appropriate dosing, ongoing haemodialysis and most importantly, the low index of suspicion due to lack of clinical experience with acyclovir neurotoxicity are probably some of the factors responsible for the delay in making the diagnosis in our case. The literature supports the use of haemodialysis to accelerate the removal of the drug and hasten neurological recovery 4, 11 . It is important to emphasize that recovery from acyclovir neurotoxicity can take up to two weeks after the drug is discontinued and that acyclovir neurotoxicity is completely reversible 4, 12 .
As the use of acyclovir increases due to the rising number of acquired immunodeficiency syndrome and transplant patients, further cases of neurotoxicity will undoubtedly be encountered. The majority of the post-transplant patients (liver transplant) are transferred to the ICU for management, where they may receive acyclovir for the first time. In sedated and ventilated patients the toxicity may surface only when attempts are made to wean the patient from sedatives and mechanical ventilation. The temporal relationship of sudden onset of symptoms to the beginning of acyclovir therapy, normal cranial scan and CSF examination, absence of fever and focal neural deficit implicate acyclovir as the causative agent. It must be remembered that neurotoxicity is more likely in the elderly, in patients with renal insufficiency or in those receiving other neurotoxic medications. The clinician should remain ever vigilant, monitoring for the signs and symptoms of acyclovir neurotoxicity when acyclovir is administered. Unless a very high level of suspicion is maintained, the diagnosis could easily be missed.
